[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatitis":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,49,82,110,139,167,193,217,239,269,305,333,373,397,421,451,476,511,539,575,597,627,649,679,700],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100645312","phase-2-phosphate-in-acute-pancreatitis-100645312",false,"NCT07681050","Phosphate in Acute Pancreatitis","Phosphate in Acute Pancreatitis (PPP)","PPP","Inclusion Criteria:\n\n* Age 18 years or older\n* Presenting to the emergency department (ED) with acute pancreatitis meeting 2 or more characteristics of: (1) typical, persistent, severe upper abdominal pain, (2) lipase or amylase levels at least three times greater than the upper limit of normal, and\u002For (3) characteristic findings on abdominal imaging)\n* Trial treatment can be initiated within 24 hours of hospital admission\n* Consent can be obtained from the patient or their legal representative\n\nExclusion Criteria:\n\nContraindications to injectable phosphate including:\n\n* Hyperkalemia\n* Hypercalcemia or significant hypocalcemia\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2) or end-stage renal disease","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this study is to learn if phosphate administration works to treat acute pancreatitis in adults presenting to the emergency department at Duke University Hospital. The main questions it aims to answer are:\n\n* Does having low phosphate levels increase the risk of acute pancreatitis and can giving phosphate through an IV make the illness less severe?\n* Is phosphate therapy practical to use, and what is the appropriate dose?\n* Is this study achievable, and how can the results help design a future randomized controlled trial to assess safety and effectiveness?\n\nParticipants will:\n\n* Receive standard of care or intravenous (IV) phosphate during their hospital stay\n* Have blood samples collected during admission to monitor phosphorus levels\n* Complete follow-up assessments after hospital admission to evaluate how severe the illness is and the effects of phosphate supplementation",[28],"Pancreatitis",[30,28,31,32,33,34,35],"Pancreas","Phosphate","Hypophosphatemia","Hyperphosphatemia","Sodium Phosphate","Potassium Phosphate","NOT_YET_RECRUITING","2026-06-26",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":22},"2026-07",{"date":44,"type":22},"2029-07",{"name":46,"class":47},"Duke University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":80,"locationsCount":48},"100641543","phase-4-indomethacin-for-biliary-ercp-patients-100641543","NCT07661498","Indomethacin for Biliary ERCP Patients","Indomethacin vs. no Indomethacin for Patients Undergoing Biliary ERCP With Prior Biliary Sphincterotomy","Inclusion Criteria:\n\n1. Male or female ≥ 18 years of age at the time of ERCP.\n2. Scheduled to undergo routine biliary ERCP with documentation of a prior biliary sphincterotomy.\n3. Ability to receive rectal medication.\n4. Ability and willingness to comply with all study procedures and follow-up requirements.\n5. Written informed consent (and assent when applicable) was obtained from the subject or the subject's legal representative, and the subject's ability to comply with the requirements of the study was confirmed.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n2. Known hypersensitivity or contraindication to indomethacin, other nonsteroidal anti-inflammatory drugs, or suppository components.\n3. Active gastrointestinal bleeding, history of NSAID-induced gastrointestinal ulceration, or other conditions that contraindicate NSAID use.\n4. Significant renal impairment (e.g., baseline serum creatinine above institutional upper limit of normal or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n5. Current use of other NSAIDs that cannot be safely discontinued per the investigator's judgment.\n6. Known chronic pancreatitis\n7. Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.",{"count":57,"type":22},860,[59],"PHASE4","This study is a randomized clinical trial evaluating the efficacy of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in patients undergoing biliary ERCP who have a history of prior biliary sphincterotomy. While rectal indomethacin has demonstrated benefits in preventing post-ERCP pancreatitis in high-risk patients, its utility in this specific patient subgroup remains unclear. This trial aims to determine whether prophylactic administration of indomethacin offers a measurable benefit over no intervention in this lower-risk population.\n\nEligible patients will be identified prior to their scheduled biliary ERCP and screened for inclusion criteria. Following informed consent, participants will be randomized to receive either rectal indomethacin or no indomethacin prior to the procedure.",[62,63,28,64,65,66],"Pancreatitis Biliary","Pancreatitis Acute Biliary","Post-ERCP Pancreatitis","Post-ERCP Acute Pancreatitis","Post-ERCP Adverse Events",[68,69,70,71,72,73],"ERCP","pancreatitis","post-ERCP pancreatitis","PEP","pancreatitis acute biliary","post-ERCP adverse events","2026-06-16",{"date":76,"type":40},"2026-06-22",{"date":42,"type":22},{"date":79,"type":22},"2031-07",{"name":81,"class":47},"University of California, San Francisco",{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100598434","indomethacin-vs-diclofenac-for-preventing-pep-100598434","NCT07071441","Indomethacin vs Diclofenac for Preventing PEP","Rectal Indomethacin Versus Diclofenac for Prevention of Post-ERCP Panceratitis (IDPPP2): A Multicenter, Double-blind, Randomized, Control Trial","Inclusion Criteria:\n\n* 18-90 years old patients with native papilla who planned to undergo ERCP\n\nExclusion Criteria:\n\n* Previous biliary sphincterotomy and papillary large balloon dilation\n* Planned for placements of pancreatic duct stents (eg. pancreatic duct strictures, planned ampullectomy)\n* Allergy to NSAIDs\n* The administration of NSAIDs within 7 days\n* Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction \\[Cr \\>1.4mg\u002Fdl=120umol\u002Fl\\]; presence of coagulopathy before the procedure)\n* Acute pancreatitis within 7 days before ERCP or acute pancreatitis with obvious Pancreatic edema and peripancreatic fluid collections\n* Hemodynamical instability\n* Pregnancy or lactation\n* Unable to give informed consent","90 Years",{"count":91,"type":22},4050,[93],"NA","Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare expenses. Preprocedural administration of rectal non-steroidal anti-inflammatory drugs (NSAIDs) was demonstrated to be an effective and convenient strategy for post-ERCP pancreatitis (PEP). Furthermore, several meta-analyses found that only 100mg indomethacin and diclofenac could effectively reduce PEP. Therefore, updated international clinical practice guidelines uniformly recommended administration of 100mg indomethacin or diclofenac in patients without contradictions. However, it was unclear which one of the two drug is more superior.\n\nA recent meta-analysis suggested 100mg rectal diclofenac was more efficacious than same-dose rectal indomethacin in PEP prevention (relative risk (RR) 0·59, 95% confidence intervals (CI) 0·40-0·89). Based on the results, we conducted a multicenter, double-blind, control trial to investigate whether 100mg diclofenac is superior than same-dose indomethacin. This trial planned to enroll 3612 patients in total. However, in the first interim analysis, PEP occurred in 53 patients (8.8%) of 600 patients allocated to diclofenac group and 37 patients (6.1%) of 604 patients allocated to indomethacin group (relative risk (RR) 1.44; 95% confidence interval (CI) 0.96-2.16, p=0.074). Thus, the trial was stopped according to the futility rule of conditional power. However, it was worth noticing that PEP tended to be higher in diclofenac group than that in indomethacin group. A sample size of 1204 was under power to draw the conclusion of significantly lower PEP rate in indomethacin group and thus a new trial with larger sample size of sufficient power is predicted to prove the superiority of indomethacin over diclofenac. Here we conducted a multicenter, randomized, double-blind trial to investigate whether 100mg indomethacin is superior to 100mg diclofenac in preventing PEP.",[68,28,96,97,98],"Non-steroidal Anti-inflammatory (NSAID)","Indomethacin","Diclofenac","RECRUITING","2026-06-12",{"date":102,"type":40},"2026-06-15",{"date":104,"type":40},"2025-06-01",{"date":106,"type":22},"2026-12-31",{"name":108,"class":47},"Air Force Military Medical University, China",20,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100642549","supraglottic-oxygenation-via-oral-transtracheal-catheter-for-reducing-the-incidence-of-hypoxemia-during-ercp-under-sedation-100642549","NCT07637721","Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation","Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation：a Randomized Controlled Trial","Inclusion Criteria:\n\n* Age≥18years\n* The ASA classification ranges from I to III\n* Patients have signed the informed consent form\n* Patients scheduled to undergo sedated ERCP examination procedure\n\nExclusion Criteria:\n\n* Severe cardiac dysfunction (\\\u003C4 METs);\n* Diagnosed chronic obstructive pulmonary disease (COPD) or other acute\u002Fchronic pulmonary diseases requiring long-term\u002Fintermittent oxygen therapy;\n* Upper respiratory tract infections including oral, nasal or pharyngeal infections;\n* Fever (core temperature \\>37.5°C);\n* Confirmed pregnancy or current breastfeeding;\n* Hypersensitivity to sedative drugs such as propofol;\n* Current participation in other clinical trials;",{"count":118,"type":22},410,[93],"Endoscopic retrograde cholangiopancreatography (ERCP) is commonly used for the diagnosis and treatment of pancreatobiliary diseases. While Monitored Anesthesia Care (MAC) enhances the efficiency of ERCP, deep sedation introduces significant airway risks, particularly hypoxemia resulting from sedative-induced upper airway collapse. With reported hypoxemia rates ranging from 10% to 69%, and the potential for severe complications such as myocardial ischemia and neurological damage, effective airway management is paramount. Supraglottic oxygenation via oral transtracheal catheter provides a viable method for relieving obstruction and enabling positive pressure ventilation, serving as a less invasive alternative to tracheal intubation. Despite its proven utility in other settings, this technique has not yet been evaluated in the context of deeply sedated ERCP.",[122,123,28,124],"Choledocholithiasis With Cholecystitis With Obstruction","Obstructive Jaundice","Cholelithiasis",[68,126,127,128,129],"Monitored Anesthesia Care","deep sedation","hypoxemia","The Supraglottic Oxygenation Via Oral Transtracheal Catheter","2026-06-09",{"date":132,"type":40},"2026-06-10",{"date":100,"type":22},{"date":135,"type":22},"2027-12-31",{"name":137,"class":47},"Zhejiang University",3,{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":48},"100569257","phase-3-evaluating-the-efficacy-of-relizorb-in-managing-exocrine-pancreatic-insufficiency-in-tube-fed-pancreatitis-patients-100569257","NCT06691893","Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients","A Randomized Controlled Trial to Evaluate the Efficacy of Immobilized Lipase (RELiZORB) During Enteral Nutrition in Patients With Exocrine Pancreatic Insufficiency Secondary to Acute Pancreatitis","Inclusion Criteria:\n\n* Patient diagnosed with moderate or severe exocrine pancreatic insufficiency (EPI), as defined using the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) symptom score of 1.4 or greater.\n* Patient diagnosed with acute, recurrent acute pancreatitis or subacute pancreatitis. Subacute pancreatitis is defined as recent diagnosis of acute pancreatitis with sequelae of the acute episode including infection, pseudocyst, walled-off pancreatic necrosis.\n* Patient is currently admitted to the hospital at the time of study enrollment.\n* Patient requiring at least 50% of daily caloric and fluid intake through enteral tube feeds.\n* Patient is able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Patient with chronic pancreatitis\n* Patient is currently intubated and unable to provide consent\n* Patient with active gastrointestinal tract cancer\n* Patient requiring less than 50% of nutritional support at time of enrollment\n* Patient is unable to tolerate any form of enteral nutrition",{"count":147,"type":22},60,[149],"PHASE3","This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammation of the pancreas. EPI occurs when the pancreas does not produce enough enzymes to help the body properly digest food. While pancreatic enzyme replacement therapy (PERT) is commonly used to manage EPI symptoms, it can be challenging for people who rely on feeding tubes. RELiZORB, could help these patients by simplifying the delivery of the enzymes they need. However, RELiZORB has only been studied in people with EPI caused by cystic fibrosis, so its effectiveness in pancreatitis patients remains unknown. This study aims to determine whether RELiZORB is effective for individuals requiring feeding tube support after pancreatitis.",[152,28],"Exocrine Pancreatic Insufficiency (EPI)",[154,69,155,156,157],"exocrine pancreatic insufficiency","RELiZORB","lipase","enteral nutrition","2026-05-12",{"date":160,"type":40},"2026-05-15",{"date":162,"type":40},"2025-03-28",{"date":164,"type":22},"2027-07-15",{"name":166,"class":47},"Massachusetts General Hospital",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":18,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":48},"100618335","cold-water-irrigation-therapy-as-an-adjunct-to-indomethacin-for-post-endoscopic-retrograde-cholangiopancreatographyercp-pancreatitis-100618335","NCT07330284","Cold Water Irrigation Therapy as an Adjunct to Indomethacin for Post-Endoscopic Retrograde Cholangiopancreatography(ERCP) Pancreatitis","Adjunctive Cold Water Irrigation Added to Rectal Indomethacin for Prevention of Post- Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis","Inclusion Criteria:\n\n* Native papilla present.\n* Undergoing ERCP for diagnostic or therapeutic indications.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Post-operative reconstructed intestinal tract other than Billroth I reconstruction.\n* Acute pancreatitis at the time of ERCP.\n* Chronic pancreatitis.\n* Pancreatic head cancer with occlusion of the main pancreatic duct.\n* Existing pancreatic duct stent or need for prophylactic pancreatic duct stenting during the index ERCP.\n* Known contraindications or allergy to indomethacin or other NSAIDs.\n* Significant renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²).\n* Active peptic ulcer disease or history of NSAID-induced gastrointestinal bleeding.","20 Years",{"count":176,"type":22},950,[93],"This study is designed to learn whether rinsing the papilla with cold water at the end of an ERCP procedure, in addition to standard medicine, can help lower the chance of developing pancreatitis, which is the most common major complication after ERCP.",[28,180],"ERCP Surgery",[182,183,68,28],"Cold Water","Prevention","2026-05-04",{"date":186,"type":40},"2026-05-07",{"date":188,"type":40},"2025-12-05",{"date":190,"type":22},"2029-12",{"name":192,"class":47},"University of Kansas Medical Center",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":48},"100585539","utility-of-trypsinogen--2-in-early-detection-and-follow-up-of-post-pancreatectomy-acute-pancreatitis-ppap-100585539","NCT06903676","Utility of Trypsinogen -2 in Early Detection and Follow Up of Post-pancreatectomy Acute Pancreatitis (PPAP)","Inclusion Criteria:\n\n* Older than 18 years of age\n* Undergoing elective pancreatectomy for any indication\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Pregnant women\n* Prisoner",{"count":200,"type":22},50,[93],"The goal of this study is to learn if urine trypsinogen can be used to diagnose post-pancreatectomy acute pancreatitis in patients undergoing pancreatectomy.\n\nParticipants will have their urine measured by dipsticks during and after their surgery.",[28,204],"Pancreatectomy",[204,206,207],"Post-pancreatectomy acute pancreatitis","PPAP","2026-03-10",{"date":210,"type":40},"2026-03-12",{"date":212,"type":40},"2025-08-05",{"date":214,"type":22},"2026-04",{"name":216,"class":47},"Indiana University",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100627945","ercp-management-in-mild-gallstone-induced-pancreatitis-patients-declining-subsequent-cholecystectomy--a-randomized-control-trial-100627945","NCT07455227","ERCP Management in Mild Gallstone-Induced Pancreatitis Patients Declining Subsequent Cholecystectomy : a Randomized Control Trial.","Comparison of Endoscopic Sphincterotomy and Conservative Management in Mild Gallstone-Induced Pancreatitis Patients Declining Subsequent Cholecystectomy : a Randomized Control Trial.","Inclusion Criteria:\n\n• Diagnosis of gallstone-related pancreatitis (classified as mild pancreatitis according to the 2012 revised Atlanta classification and definitions).\n\n• Imaging studies reveal the presence of gallstones or sludge, along with at least one of the following conditions: i. Imaging evidence of common bile duct dilation (common bile duct diameter \\> 8 mm for patients aged ≤ 75 years; \\> 10 mm for patients aged \\> 75 years).\n\nii. Biochemical evidence of cholestasis with total bilirubin levels between 1.8 - 4 mg\u002FdL.\n\niii. Alanine aminotransferase (ALT) levels greater than twice the upper limit of normal.\n\n\\-","80 Years",{"count":226,"type":22},30,[93],"to investigate the role and potential benefits or drawbacks of ERCP with sphincterotomy in patients declining subsequent cholecystectomy for gallstone-induced pancreatitis.",[28],"2026-03-03",{"date":232,"type":40},"2026-03-06",{"date":234,"type":22},"2026-04-01",{"date":236,"type":22},"2028-05-01",{"name":238,"class":47},"Fu Jen Catholic University Hospital",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":48},"100451592","phase-2-corticosteroids-to-treat-pancreatitis-100451592","NCT05160506","Corticosteroids to Treat Pancreatitis","Corticosteroids to Reduce Inflammation in Severe Pancreatitis: A Randomized, Controlled Study","CRISP","Inclusion Criteria:\n\n1. Adult (≥18 years)\n2. Acute pancreatitis as defined by a clinical diagnosis of pancreatitis and a lipase level ≥3x the upper limit of normal.\n3. Admission or planned admission to an intensive care unit\n4. SOFA disease severity score ≥3 (or at least 3 points above a known baseline)\n\nExclusion Criteria:\n\n1. Known diagnosis of autoimmune pancreatitis\n2. Existing clinical indication for corticosteroids at a dose \\>5mg of oral prednisone daily (or equivalent)\n3. Contraindication to receiving corticosteroids\n4. Protected populations (prisoners)\n5. Pregnancy","99 Years",{"count":249,"type":22},86,[25],"This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.",[28,253,254,255],"Pancreatitis, Acute","Corticosteroid","Hydrocortisone",[257,258,259],"Bedside index of severity in acute pancreatitis","Sequential Organ Failure Assessment","Randomized Controlled Trial","2026-02-16",{"date":262,"type":40},"2026-02-18",{"date":264,"type":40},"2022-03-06",{"date":266,"type":22},"2027-04",{"name":268,"class":47},"Beth Israel Deaconess Medical Center",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":276,"targetDuration":278,"studyType":279,"phases":4,"briefSummary":280,"conditions":281,"keywords":287,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":304},"100268556","pancreas-registry-and-high-risk-registry-100268556","NCT02775461","Pancreas Registry and High Risk Registry","Pancreas Disease and High Risk Registry","Inclusion Criteria:\n\n* At least 1 first degree relative affected with Pancreatic Cancer\n* Any of (BRCA1, BRCA2, PALB2, ATM) mutations + 1 family member with Pancreatic Cancer\n* mFAMMM (p16,CDKN2A mutations) + 1 family member with Pancreatic cancer\n* Known mutation carrier for STK11 (Peutz Jeghers Syndrome)\n* Lynch syndrome (HNPCC) + 1 family PDAC\n* Known mutation carrier for Hereditary pancreatitis\n* Individuals with a history of pancreatic cyst(s) (IPMN's) that measure ≥ 1 cm\n\nExclusion Criteria:\n\n* Patients who do not speak English or Spanish\n* Refusal by patient\n* Individuals under the age of 18 years",{"count":277,"type":22},1368,"10 Years","OBSERVATIONAL","The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of the pancreas, cystic lesions of the pancreas, and patients at high-risk of pancreatic cancer such as those with a family history of pancreatic cancer or with a family history of a syndrome known to be associated with pancreatic cancer. Pancreatic cancer is the fourth leading cause of death from cancer in the United States. However, little is known about the development of pancreatic cancer and pancreatic diseases in individuals with the above conditions. Knowledge of how family history, environmental exposures, and inflammatory lesion of the pancreas contribute to the development of pancreatic cancer and pancreatic diseases is essential.\n\nYou may qualify to take part in this research study because you have inflammation in the pancreas, a pancreatic cyst, pre-cancerous lesions of the pancreas, pancreatic cancer, a family history of pancreatic cancer, or a family history of a syndrome known to be associated with pancreatic cancer.\n\nWe will also be collecting a blood sample from all participants for DNA isolation. Sometimes we are born with genes or DNA that give us an increased or decreased chance of developing an illness later in life. Genetic material will be isolated from your blood for further study. You may also choose to provide additional blood samples for serum and plasma extraction. Serum and plasma are components of the blood which can be used to measure indicators of disease in the blood, called biomarkers,for pancreatic diseases. Clinical data and biological specimens contained in this study may be used for a wide variety of future related studies to the cause, diagnosis, outcome and treatment of pancreatic cancer.\n\nFunds for conducting this research are provided by Mount Sinai.",[282,28,283,284,285,286],"Pancreas Cancer","Chronic Pancreatitis","Pancreatic Cyst","Family History of Pancreas Cancer","Genetic Mutations",[282,283,284,288,289,290,291,292,293,28,285,294],"BRCA1","BRCA2","Lynch Syndrome","Peutz-Jeghers syndrome","ATM mutation","FAMMM Syndrome","Family History of Cancer","2026-02-09",{"date":297,"type":40},"2026-02-11",{"date":299,"type":40},"2013-03-01",{"date":301,"type":22},"2033-01",{"name":303,"class":47},"Icahn School of Medicine at Mount Sinai",2,{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":48},"100545770","internet-delivered-pain-self-management-for-persons-with-acute-recurrent-and-chronic-pancreatitis-pain-100545770","NCT06386224","Internet-Delivered Pain Self-Management for Persons With Acute Recurrent and Chronic Pancreatitis Pain","Internet-Delivered Pain Self-Management to Reduce Pain and Interference in Chronic Pancreatitis","IMPACT-2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willingness to use personal device with internet access (smart phone, computer, iPad) or to borrow a study iPad\u002Fhotspot\n* Diagnosis of CP defined as having obvious morphological features of CP (i.e., Cambridge 3-4 stage or the presence of pancreatic calcifications on CT scan and\u002For magnetic resonance cholangiopancreatography)\n* Diagnosis of RAP defined as having abdominal pain of a duration of \\>=3 months, one episode of acute pancreatitis (AP), or RAP.\n* Having experienced moderate pain intensity (rated as 4 or higher on a 0-10 Numerical Rating Scale) in the last month from RAP or CP.\n\nExclusion Criteria:\n\n* Undergoing treatment for cancer\n* Unable to read English well enough to complete questionnaires or read the study website\n* Currently experiencing suicidal ideation\n* Having received endoscopic therapy in the past 30 days\n* Currently receiving treatment from a psychologist (\\> 4 sessions)",{"count":314,"type":22},280,[93],"Severe and disabling abdominal pain is common in individuals with chronic pancreatitis. Although pain is associated with reduced quality of life and high economic and societal costs, there are limited effective options for pain management in this population. This study proposes an evidence-based psychological intervention approach using an internet-delivered pain self-management program to minimize the impact of pain and improve quality of life. The ultimate goal is to maximize the public health impact of the intervention with successful implementation and dissemination to pancreas clinics and to the community.",[28,283,318],"Acute Recurrent Pancreatitis",[28,320,321,322,323],"Pain","Internet Intervention","Behavioral Intervention","Cognitive Behavioral Therapy","2026-01-19",{"date":326,"type":40},"2026-01-21",{"date":328,"type":40},"2024-05-01",{"date":330,"type":22},"2026-09-30",{"name":332,"class":47},"Seattle Children's Hospital",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":23,"phases":343,"briefSummary":344,"conditions":345,"keywords":355,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":48},"100613159","phase-4-preventing-postoperative-complications-in-patients-undergoing-high-risk-pancreatoduodenectomy-with-a-bundle-approach-including-hydrocortisone-octreotide-and-the-teres-ligament-patch-panenca-100613159","NCT07262957","Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)","Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA): an International Randomized Controlled Multicenter Trial","PANENCA","Inclusion Criteria:\n\n* Elective pancreatoduodenectomy for any indication (both minimally invasive and open)\n* Pancreatic duct diameter ≤ 3mm on preoperative CT or MRI\\*\n* 18 years of age or older\n* Signature of informed consent\n* In the opinion of the investigator, the patient is eligible for the administration of hydrocortisone and octreotide, based on contraindications, warnings, and precautions as listed in the respective SmPCs\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy or current breastfeeding\n* Known allergy or hypersensitivity to hydrocortisone or octreotide\n* Systemic fungal infection\n* Concomitant use of strong CYP3A4 inhibitors or moderate-to-strong inducers that cannot be discontinued (see CYTOCHROME P450 DRUG INTERACTION TABLE (iu.edu))\n\n  * Inhibitors must be discontinued ≥7 days before randomization\n  * Inducers must be discontinued ≥28 days before randomization",{"count":342,"type":22},400,[59],"The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of the pancreas. One of the most frequent and serious complications after this surgery is postoperative pancreatic fistula (POPF), a leakage of pancreatic fluid from the surgical connection. POPF can lead to intra-abdominal infection, bleeding, and inflammation, often resulting in delayed recovery and postponement of subsequent oncological treatment. In severe cases, these complications may be life-threatening.\n\nPatients with a small main pancreatic duct (3 millimeters or less) are known to have a substantially higher risk of developing POPF. Previous studies have shown that several existing interventions may reduce the risk or severity of these complications. These include hydrocortisone, a medication that suppresses postoperative inflammation; octreotide, a medication that reduces the production of pancreatic secretions; and a surgical technique known as the ligamentum teres hepatis patch, which uses the patient's own tissue to protect nearby blood vessels in the event of a pancreatic leak.\n\nBecause the development of pancreatic fistulas is multifactorial, the investigators hypothesize that a combined approach targeting different underlying mechanisms may provide a complementary and more effective protective effect than any single intervention alone. The PANENCA trial therefore evaluates whether the combined use of hydrocortisone, octreotide, and the ligamentum teres patch can reduce the rate of major postoperative complications after pancreatoduodenectomy.\n\nPatients participating in the study are randomly assigned to receive either the combination treatment in addition to standard perioperative care or standard perioperative care alone. The study medications are administered only during the first postoperative days, and the surgical patch is applied during the operation itself. No additional tests, monitoring procedures, or hospital visits are required beyond routine clinical care.\n\nThis international, multicenter randomized trial includes patients at high risk for POPF who are undergoing pancreatoduodenectomy. The primary objective is to determine whether the combination treatment reduces the incidence of major postoperative complications. If proven effective, this bundle approach may be implemented more consistently across participating countries and incorporated into international clinical guidelines for pancreatic surgery.",[346,347,348,349,350,351,352,353,354,28],"Pancreas Head Cancer","Pancreas Adenocarcinoma","IPMN, Pancreatic","Cholangio Carcinoma","Ampulla of Vater Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Duodenal Carcinoma","Mucinous Cystic Neoplasm","Neuro Endocrine Tumours",[356,357,358,359,360,361,255,362,363],"Whipple","Pancreatoduodenectomy","POPF","Major complications","Fistula","ISGPS","Octreotide","Ligament teres patch","2025-12-16",{"date":366,"type":40},"2025-12-22",{"date":368,"type":40},"2025-09-01",{"date":370,"type":22},"2027-12-01",{"name":372,"class":47},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":380,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":48},"100599328","phase-4-precise-endoscopic-application-of-nitroglycerin-in-preventing-post-ercp-pancreatitis-100599328","NCT07083063","Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis","Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Eligible participants include patients aged ≥ 18 years who accept ERCP and sphincterotomy for common bile duct (CBD) stone extraction.\n\nExclusion Criteria:\n\n* patients with pancreatic cancer\n* shock status (systolic blood pressure \\\u003C 90 mmHg or using inotropic agents)\n* allergy to NTG\n* angle-closure glaucoma\n* severe anemia\n* patients on PDE 5 inhibitors",true,{"count":382,"type":22},440,[59],"Endoscopic retrograde cholangiopancreatography (ERCP) is a technically demanding procedure combining endoscopy and fluoroscopy to diagnose and treat pancreaticobiliary disorders such as bile duct stones, strictures, and cholangitis. Despite its therapeutic value, ERCP carries a relatively high complication risk of about 10%, with severe complications occurring in roughly 24% of those affected and mortality rates between 0.2% and 0.7%. The most common and significant complication is post-ERCP pancreatitis (PEP), occurring in 2% to 10% of average patients and up to 40% or higher in high-risk groups. PEP ranges from mild, self-limiting inflammation to severe, life-threatening conditions including pancreatic necrosis and multi-organ failure.\n\nPEP arises from mechanical trauma, hydrostatic injury, chemical irritation, or infection during ERCP that activates inflammatory pathways within the pancreas. Key patient-related risk factors include young age, female sex, prior pancreatitis, and sphincter of Oddi dysfunction; procedural factors include difficult biliary cannulation, pancreatic duct manipulation, and precut sphincterotomy.\n\nPreventive strategies focus on minimizing mechanical injury and pharmacologic prophylaxis. Rectal NSAIDs (indomethacin, diclofenac) administered immediately before ERCP are well-supported for reducing PEP risk. Periprocedural aggressive intravenous hydration and prophylactic pancreatic duct stenting in high-risk cases also lower PEP incidence.\n\nNitroglycerin, a smooth muscle relaxant acting via nitric oxide-mediated sphincter relaxation, has shown promise in PEP prevention, especially in patients contraindicated for NSAIDs. Clinical trials indicate that transdermal or sublingual nitroglycerin reduces PEP rates, and combined use with NSAIDs may enhance protection. However, current guidelines do not routinely recommend nitroglycerin due to limited consensus on its efficacy.\n\nTopical nitroglycerin, known to relax smooth muscles locally and used in anorectal conditions, might reduce sphincter of Oddi pressure without systemic side effects. This suggests potential benefit in lowering PEP incidence or severity when applied topically during ERCP, pending further investigation. This study aimed to investigate whether topical delivery of nitroglycerin can reduce the incidence rate of PEP or the severity of pancreatitis.",[28],[70,387],"nitroglycerin","2025-12-01",{"date":390,"type":40},"2025-12-08",{"date":392,"type":40},"2025-09-15",{"date":394,"type":22},"2027-07-31",{"name":396,"class":47},"National Cheng-Kung University Hospital",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":380,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":279,"phases":4,"briefSummary":406,"conditions":407,"keywords":410,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":420},"100311460","a-study-of-blood-based-biomarkers-for-pancreas-adenocarcinoma-100311460","NCT03334708","A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma","Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution\n* Patient planning to receive systemic treatment\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution\n* Patient planned to undergo upfront resection\n* No pre-operative systemic therapy nor chemoradiation therapy planned\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 5: IPMN Control Inclusion Criteria\n\n* Confirmed diagnosis of IPMN without high risk features by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 6: Pancreatic Cyst Control Inclusion Criteria\n\n* Confirmed diagnosis of benign pancreatic cyst by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 7: Healthy Control Inclusion Criteria\n\n* A minimum age of 18 years old\n\nExclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria\n\n* Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria\n\n* Neoadjuvant chemotherapy or radiation therapy is planned\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 5: IPMN Control Exclusion Criteria\n\n* IPMN with high risk features or planned resection\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 6: Pancreatic Cyst Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 7: Healthy Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures",{"count":405,"type":22},700,"The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.",[408,409,28,284],"Pancreatic Cancer","Pancreatic Diseases",[411],"17-257",{"date":413,"type":40},"2025-12-02",{"date":415,"type":40},"2017-10-30",{"date":417,"type":22},"2026-10-30",{"name":419,"class":47},"Memorial Sloan Kettering Cancer Center",13,{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":428,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":436,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":48},"100590460","building-and-sustaining-exercise-habits-for-adults-with-type-1-diabetes-100590460","NCT06967701","Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes","Informatics-Based Digital Intervention to Promote Safe Exercise in Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes - A Pilot Efficacy Study","Inclusion criteria:\n\n* 30-65 years old inclusive\n* Diagnosis with type 1 diabetes (T1D) or other insulin deficiency diabetes (latent autoimmune disease of adulthood, diabetes secondary to pancreatitis)\n* Less than 1.0 exercise sessions per week\n* Smartphone ownership\n* English literacy\n* Under regular care by a healthcare provider (1+ appointments per year)\n* Home Broadband wireless Internet or cell phone network\n* Using continuous glucose monitor (CGM) and sharing data with medical record for at least 6 weeks\n* Using insulin pump or pen and sharing data with medical record for at least 6 weeks\n\nExclusion criteria:\n\n* Diabetic ketoacidosis not clearly related to pump site failure in past 6 months\n* \\>1 episode of severe hypoglycemia (altered mental and\u002For physical status requiring assistance from another person for recovery) in past 6 months\n* A1c ≥10.0%\n* Resting blood pressure \\>160mmHg systolic or \\>100 mmHg diastolic.\n* Myocardial infarction or angina in past 12 months\n* Uncontrolled arrhythmia (e.g., atrial fibrillation with rapid ventricular response, new onset atrial fibrillation, ventricular tachycardia, escape rhythms)\n* Congestive heart failure (stage 3 or 4)\n* Exercise-induced asthma (not controlled on inhalers)\n* Chronic obstructive pulmonary disease (requiring home oxygen)\n* Renal failure\n* Pregnancy\n* Cognitive impairment\n* Severe retinopathy or neuropathy.\n* Other chronic disease or physical disability that would influence exercise intervention (e.g., recent spinal surgery)","30 Years","65 Years",{"count":147,"type":22},[93],"The challenges of living with type 1 diabetes often stand in the way of getting enough exercise. Continuous blood sugar monitoring has revolutionized type 1 diabetes care but remains underutilized to sustainably support exercise and related behaviors. This remote participation-based research will develop a mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently. You do not need to live in Connecticut to participate, as there will be no required in-person visits during the study.",[434,435,28],"Type 1 Diabetes (T1D)","Latent Autoimmune Diabetes in Adult (LADA)",[437,438,439,440,441],"exercise","physical activity","mobile phone","health coaching","fitness watch","2025-11-04",{"date":444,"type":40},"2025-11-06",{"date":446,"type":40},"2025-07-10",{"date":448,"type":22},"2027-07",{"name":450,"class":47},"Yale University",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":279,"phases":4,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":48},"100293437","prospective-evaluation-of-chronic-pancreatitis-for-epidemiologic-and-translational-studies-100293437","NCT03099850","Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies","Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies - PROCEED Study","Inclusion Criteria:\n\n1\\. Participants with chronic pancreatitis.\n\nExclusion Criteria:\n\nALL GROUPS EXCEPT GREEN GROUP I:\n\n1. History of autoimmune or traumatic pancreatitis, or sentinel attack of acute necrotizing pancreatitis which results in suspected\n2. Primary pancreatic tumors - pancreatic ductal adenocarcinoma, suspected cystic neoplasm (\\>1 cms in size or main duct involvement), neuroendocrine tumors, and other uncommon tumors.\n3. Pancreatic metastasis from other malignancies.\n4. History of solid organ transplant, HIV\u002FAIDS.\n5. Known isolated pancreatic exocrine insufficiency (e.g. in the absence of any eligible inclusion criteria).\n6. Participants must not have medical or psychiatric illnesses or ongoing substance abuse that in the investigator's opinion would compromise their ability to tolerate study interventions or participate in longitudinal follow up.\n7. Patients with known abnormal creatinine (GFR \\\u003C 30) or renal failure (applies to patients with chronic upper abdominal pain of suspected pancreatic origin and suspected CP (Yellow) subgroups).\n8. Failure to agree for longitudinal follow-up.\n9. Known Pregnancy. All participants of childbearing potential, except if post-menopausal \\[i.e. no menses for ≥2 years\\] or had a hysterectomy, bilateral tubal ligation\u002Fclip (surgical sterilization) or surgical removal of both the ovaries), must have a negative urine or serum B-HCG pregnancy test documented within 2 days prior to any endoscopic or radiologic procedures done for research purposes. Any standard of care tests will follow institutional policies regarding pregnancy test.\n10. Currently incarcerated.\n11. Inability to get MRI\u002FMRCP in patients with chronic abdominal pain of suspected pancreatic origin (Green II) or Suspected CP (Yellow groups) at baseline (e.g. metal object in the body which precludes performance of MRI).","75 Years",{"count":460,"type":22},2345,"The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCCEED) Study, which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). No patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC. The data management systems, auditing, and monitoring effort are supported by the MD Anderson Cancer Center Clinical Research Support Center (CRSC).\n\nPROCEED is the first study in the USA that is carefully following participants to better understand factors that may be responsible for causing pancreatitis and how it progresses. The study is being conducted at the following 9 major clinical centers across the US:\n\n* Baylor College of Medicine\n* Cedars-Sinai Medical Center\n* University of Florida\n* Indiana University\n* Mayo Clinic\n* University of Minnesota\n* Ohio State University\n* Stanford University\n* University of Pittsburgh\n\nThe study is enrolling participants who are at different stages of chronic pancreatitis, including those with no known pancreas disease (controls), and those with abdominal pain, one or more attacks of pancreatitis, or chronic pancreatitis. After enrollment, participants with abdominal pain and pancreatitis are asked to follow-up every year to learn about their symptoms and any changes in the disease. PROCEED investigators plan to use the detailed information they collect to better understand the disease and identify new treatments.\n\n\"More details and updated information about this study can be found at the study's public website: https:\u002F\u002Fwww.cpdpc-research-consortium.org\u002Fresearch- study-cpdpc-16-02-proceed\".",[28],[283,464,465,466],"Data management","Regulatory compliance","Protocol monitoring","2025-10-10",{"date":469,"type":40},"2025-10-14",{"date":471,"type":40},"2017-02-28",{"date":473,"type":22},"2030-06-30",{"name":475,"class":47},"M.D. Anderson Cancer Center",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":279,"phases":4,"briefSummary":486,"conditions":487,"keywords":494,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100607133","nucleosome-monitoring-relevance-for-outcome-prediction-in-critically-ill-patients-100607133","NCT07184593","Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients","Validation of a Point-of-care Device for Rapid Bedside Measurement of Circulating Nucleosome Levels in Critically Ill Patients and Study of Its Relevance to Prognostication","NuROPI","Inclusion Criteria:\n\n* Admission to the intensive care unit (ICU) within the past 24 hours.\n* Patient must meet one of the following conditions:\n\nSepsis, defined according to SEPSIS-3 criteria.\n\nSeptic shock, defined according to SEPSIS-3 criteria.\n\nCardiogenic shock, classified as Stage C according to the Society for Cardiovascular Angiography and Interventions (SCAI).\n\nSevere trauma requiring transfusion of four or more units of red blood cells within six hours.\n\nAcute brain injury requiring invasive neuromonitoring.\n\nPost-cardiac arrest with at least 15 minutes of no or low perfusion.\n\nSevere acute pancreatitis requiring ICU-level care.\n\n\\- Presence of an arterial or central venous catheter to allow blood sampling.\n\nExclusion Criteria\n\n* Patient who has expressed opposition to participate.\n* Age younger than 18 years.\n* Imminent death with an expected survival of less than 24 hours.\n* Presence of therapeutic limitations (e.g., no indication for intubation).\n* Active cancer.\n* Absence of the required vascular access.\n* ICU admission longer than 24 hours prior to screening.\n* Readmission of a previously enrolled patient.",{"count":485,"type":22},130,"The goal of this observational study is to evaluate whether whole blood H3.1 nucleosome levels can predict 30-day mortality in adult critically ill patients admitted to the ICU with conditions such as sepsis, septic shock, cardiogenic shock, severe trauma, post-cardiac arrest, acute brain injury, or severe acute pancreatitis.\n\nThe main questions it aims to answer are:\n\nDo initial whole blood H3.1 nucleosome levels predict 30-day mortality in critically ill patients?\n\nAre whole blood nucleosome measurements using a novel point-of-care device correlated with traditional plasma chemiluminescence immunoassays (ChLIA)?\n\nIf there is a comparison group: Researchers will compare point-of-care whole blood nucleosome results with plasma ChLIA assays to see if the device provides reliable and feasible bedside measurements.\n\nParticipants will:\n\nProvide blood samples at admission, 6h, Day 1, Day 3, and Day 7 for nucleosome analysis.\n\nUndergo point-of-care H3.1 nucleosome measurement and parallel plasma storage for ChLIA testing.\n\n(If applicable, in acute brain injury patients with external ventricular drains) provide daily cerebrospinal fluid samples until Day 5, only if otherwise discarded.\n\nHave standard ICU data (SOFA, SAPS II, etc.) collected as part of routine care.",[488,489,490,28,491,492,493],"Sepsis","Septic Shock","Cardiac Arrest (CA)","Acute Brain Injury","Trauma Blunt","Cardiogenic Shock",[495,496,497,498,499,500,501],"nucleosome","septic shock","Histones","Cardiac Arrest","Cardiogenic shock","Trauma","Acute brain injury","2025-09-17",{"date":504,"type":40},"2025-09-22",{"date":506,"type":22},"2025-10-01",{"date":508,"type":22},"2027-09-30",{"name":510,"class":47},"Erasme University Hospital",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":23,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":48},"100606365","scrambler-therapy-in-chronic-pancreatitis-100606365","NCT07174609","Scrambler Therapy in Chronic Pancreatitis","A Pilot Study of Scrambler Therapy for Painful Chronic Pancreatitis","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Diagnosis of chronic pancreatitis with refractory abdominal pain\n* Able to provide written informed consent in English\n* Sufficient English language ability to complete study questionnaires\n* Reliable and regular access to a phone for follow-up\n\nExclusion Criteria:\n\n* Unable or unwilling to provide written consent\n* History or presence of a significant medical or psychiatric condition that would interfere with study participation\n* Pregnant or lactating women\n* Coronary stents or implanted metallic\u002Felectrical devices (pacemaker, defibrillator, aneurysm clips)\n* History of epilepsy, traumatic brain injury, or myocardial infarction within the past 6 months\n* Skin conditions preventing electrode placement (e.g., open wounds)\n* Any condition that, in the investigator's opinion, places the participant at increased risk or prevents full compliance with study procedures",{"count":519,"type":22},40,[93],"The investigators will enroll adults with chronic pancreatitis who have persistent abdominal pain not relieved by standard treatments. This study will test the feasibility and effectiveness of Scrambler Therapy, a non-invasive FDA-cleared device that delivers \"non-pain\" electrical signals through the skin to retrain the brain's pain perception. Participants will undergo 5-10 treatment sessions and be followed for 3 months with standardized pain scores and quality-of-life assessments. The goal is to generate pilot data to support larger studies of Scrambler Therapy as a novel option for pancreatic pain.",[523,28,283],"Chronic Pain",[525,526,527,528,529],"chronic pain","Abdominal pain","chronic pancreatitis","Scrambler Therapy","Electrocutaneous analgesia","2025-09-11",{"date":532,"type":40},"2025-09-16",{"date":534,"type":40},"2024-11-01",{"date":536,"type":22},"2026-12-01",{"name":538,"class":47},"Johns Hopkins University",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":547,"targetDuration":549,"studyType":279,"phases":4,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":574},"100450503","cytosorb-treatment-of-critically-ill-patients-registry-100450503","NCT05146336","CytOSorb TreatMent Of Critically Ill PatientS Registry","CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting","COSMOS","Inclusion Criteria:\n\n1. Planned OR actual CytoSorb® 300 mL device utilization\n2. Informed consent for prospective registry participation\n\nExclusion Criteria:\n\n1. Use of the CytoSorb® 300 mL device for antithrombotic removal only\n2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only\n3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.",{"count":548,"type":22},3000,"3 Months","Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care",[489,552,500,553,493,28,554,555,556,557,558,559,560,561,562,563,564,488],"Acute Respiratory Distress Syndrome","Rhabdomyolysis","Acute on Chronic Liver Failure","Acute Liver Failure","Burns","Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)","Extracorporeal Life Support","Postoperative Endocarditis","Hemophagocytic Lymphohistiocytoses","Liver Transplant; Complications","Infectious Disease","Postoperative Vasoplegic Syndrome","Drug Overdose","2025-09-10",{"date":530,"type":40},{"date":568,"type":40},"2022-06-22",{"date":570,"type":22},"2032-09",{"name":572,"class":573},"CytoSorbents, Inc","INDUSTRY",28,{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":583,"targetDuration":585,"studyType":279,"phases":4,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":304},"100606261","proms-after-pancreatectomy-100606261","NCT07173257","PROMs After Pancreatectomy","Patient Reported Outcomes Measures in Patients Undergoing Pancreatic Resections","PERSPECTIVE","Inclusion Criteria:\n\n* Patients \\>18 years old who undergo pancreatic resection for any indication of any race, gender, or ethnicity who are fluent in English\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* Deemed not to have capacity to consent.",{"count":584,"type":22},250,"2 Years","The standard of care for a patient with resectable pancreatic is to perform pancreatic resection which, even in the modern era is associated with significant complications and impact on quality of life, often in the setting of poor survival even in the best scenario. Currently, there is a lack of data on patient quality of life after such procedures, how quality of life changes throughout the course of care, and whether patients who undergo these procedures are satisfied with their decision. This research is aimed to understand the impact of pancreatic surgery on patients' quality of life, how that impact changes over time, and patient satisfaction (or regret) with their decisions. This work will help improve the pre-operative conversation to help patients decide whether undergoing a pancreatic resection aligns with their post-operative goals of care.",[588,28,284],"Pancreas Neoplasms","2025-09-08",{"date":392,"type":40},{"date":592,"type":40},"2023-04-03",{"date":594,"type":22},"2026-12",{"name":596,"class":47},"University of Arizona",{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":604,"maxAge":19,"enrollmentInfo":605,"targetDuration":4,"studyType":23,"phases":607,"briefSummary":608,"conditions":609,"keywords":614,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":48},"100594803","phase-4-comparison-of-the-effectiveness-of-paracetamol-with-ibuprofen-or-paracetamol-with-metamizole-in-treating-pain-in-acute-pancreatitis-in-children-100594803","NCT07024199","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children: a Randomized Trial","Inclusion Criteria:\n\n* diagnosis of AP according to the INSPPIRE mentioned above criteria,\n* age from 3 to 18 years of age,\n* abdominal pain on admission assessed on the Numerical Rating Scale (NRS) or FLACC \\>= 4 points,\n* no analgesic treatment before enrolment in the study OR the last dose of analgesic drug (paracetamol, ibuprofen, metamizole) taken ≥ 6 hours before enrolment for examination,\n* consent of legal guardians and the child (in the case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria - patients:\n\n* who took the last dose of painkiller (paracetamol, ibuprofen, metamizole) \\\u003C 6 hours before entering the study,\n* allergic to acetylsalicylic acid, other NSAIDs, paracetamol, metamizole,\n* with inflammatory bowel disease,\n* with gastrointestinal bleeding and other active bleeding,\n* with gastric and\u002For duodenal ulcer disease,\n* chronically taking paracetamol, NSAIDs, metamizole,\n* with liver failure,\n* with heart failure according to the NYHA II-IV scale,\n* with acute and chronic renal failure,\n* with cancer,\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients \\> 16 years of age).","3 Years",{"count":606,"type":22},78,[59],"The aim of the study is to assess the effectiveness and tolerance of pain treatment in AP in children using intravenous paracetamol in combination with ibuprofen or paracetamol in combination with metamizole. The study is prospective, interventional, and randomized.",[253,610,611,409,612,28,613],"Pain, Acute","Pancreatic Disease","Gastroenterology","Paediatrics",[615,616,617,69],"acute pancreatitis","acute pain","painkillers","2025-08-18",{"date":620,"type":40},"2025-08-24",{"date":622,"type":22},"2025-09",{"date":624,"type":22},"2027-06-01",{"name":626,"class":47},"Medical University of Warsaw",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":636,"briefSummary":637,"conditions":638,"keywords":640,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":647,"locationsCount":48},"100603084","bedside-monitoring-of-microenvironmental-changes-in-infected-pancreatic-collections-100603084","NCT07131917","Bedside Monitoring of Microenvironmental Changes in Infected Pancreatic Collections","Feasibility, Safety and Clinical Impact of Bedside Microenvironmental Monitoring in Infected Walled-Off Pancreatic Necrosis During Standard Percutaneous Drainage","WOPN-MONITOR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of walled-off pancreatic necrosis (WOPN) confirmed by imaging (CT, MRI, or EUS)\n* Clinical suspicion or confirmation of infection in WOPN (e.g., fever, elevated inflammatory markers, positive culture)\n* Planned percutaneous drainage as part of standard care\n* Ability to provide informed consent (or surrogate consent where applicable)\n\nExclusion Criteria:\n\n* Coagulopathy not correctable prior to intervention (e.g., INR \\> 2.0 or platelets \\\u003C 50×10⁹\u002FL)\n* Known allergy or hypersensitivity to materials used in the monitoring probe\n* technical limitations precluding safe probe insertion",{"count":109,"type":22},[93],"This pilot clinical study aims to assess the feasibility and clinical relevance of bedside monitoring of microenvironmental conditions within infected walled-off pancreatic necrosis (WOPN).\n\nWOPN is a serious complication of acute pancreatitis, often associated with infection, organ failure, and the need for drainage or surgical intervention. Although infection is a key factor in prognosis, little is known about the local chemical environment inside the infected collections.\n\nIn this study, a sterile, miniaturized probe will be temporarily introduced into the necrotic cavity during standard percutaneous drainage. The goal is to record local microenvironmental parameters (such as acidity or related values) and monitor their changes over time.\n\nBy comparing these values with clinical data (e.g., inflammatory markers, microbiology, need for surgery), the study aims to determine whether such measurements can provide additional information about infection severity and treatment response.\n\nThe study does not involve any experimental treatment. All patients will receive standard medical care, including antibiotics, imaging, and drainage according to international guidelines.\n\nParticipation is voluntary. Only patients who provide informed consent will be enrolled.",[28,639],"Walled Off Pancreatic Necrosis",[69],"2025-08-13",{"date":643,"type":40},"2025-08-20",{"date":645,"type":22},"2025-11-01",{"date":102,"type":22},{"name":648,"class":47},"Martin Harazim",{"id":650,"slug":651,"hasResults":12,"nctId":652,"briefTitle":653,"officialTitle":654,"acronym":655,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":23,"phases":659,"briefSummary":660,"conditions":661,"keywords":666,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":674,"leadSponsor":676,"locationsCount":678},"100601119","encapsulation-oriented-vs-timing-oriented-strategies-for-necrotizing-pancreatitis-100601119","NCT07106346","Encapsulation-oriented vs. Timing-oriented Strategies for Necrotizing Pancreatitis","Encapsulation-oriented Versus Timing-oriented Strategies for the Timing of Endoscopic Ultrasound-guided Drainage in Necrotizing Pancreatitis After Acute Pancreatitis: A Multicenter Randomized Controlled Trial (WONDER-03)","WONDER-03","Inclusion Criteria:\n\n* Patients diagnosed with necrotizing pancreatitis according to the revised Atlanta classification, confirmed by contrast-enhanced CT (plain CT or MRI may be substituted if contrast-enhanced CT is not feasible).\n* Within 28 days of onset of acute pancreatitis.\n* Age ≥ 18 years at the time of consent, regardless of sex.\n* Provided written informed consent from the patient or a legally authorized representative after sufficient explanation.\n* Patients who are either hospitalized or being followed as outpatients at participating study institutions.\n\nExclusion Criteria:\n\n* Unknown date of onset of acute pancreatitis.\n* Patients who have already undergone transluminal drainage with stent placement for necrotizing pancreatitis.\n* Diagnosis of chronic pancreatitis.\n* Patients for whom endoscopic treatment is deemed unsafe.\n* Pregnant women.\n* Patients deemed inappropriate for the study by the principal investigator or sub-investigator.",{"count":658,"type":22},224,[93],"This multicenter, randomized controlled trial (WONDER-03 study) investigates the optimal timing for endoscopic ultrasound (EUS)-guided drainage in patients with necrotizing pancreatitis. Although current guidelines recommend delaying drainage until at least four weeks after the onset of acute pancreatitis to allow for encapsulation of necrosis, recent observational data suggest that the degree of encapsulation itself may more strongly influence treatment success and safety. In this trial, patients are randomly assigned to one of two groups: an encapsulation-oriented group, in which EUS-guided drainage is performed when imaging confirms ≥80% encapsulation of the necrotic collection with symptoms, and a timing-oriented group, in which drainage is performed at four to five weeks after disease onset, regardless of encapsulation status. The primary endpoint is clinical success within 180 days, defined as both radiologic resolution of necrosis and improvement in symptoms. Secondary endpoints include adverse event rates, recurrence of fluid collections, technical and clinical success rates, and healthcare resource use. This study aims to determine whether a strategy based on encapsulation leads to better clinical outcomes than the conventional time-based approach and may help establish a new evidence-based treatment algorithm for necrotizing pancreatitis.",[662,28,663,664,665],"Walled Off Necrosis","Acute Necrotic Collection","Necrotizing Pancreatitis","Pancreatitis, Acute Necrotizing",[667,668,662,669,69],"Endosonography","Drainage","necrotizing pancreatitis","2025-07-30",{"date":672,"type":40},"2025-08-06",{"date":212,"type":22},{"date":675,"type":22},"2028-07-31",{"name":677,"class":47},"Tokyo University",36,{"id":680,"slug":681,"hasResults":12,"nctId":682,"briefTitle":683,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":685,"targetDuration":4,"studyType":23,"phases":686,"briefSummary":687,"conditions":688,"keywords":689,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":699,"locationsCount":48},"100596938","phase-2-feasibility-and-safety-of-supraglottic-oxygen-delivery-via-an-endotracheal-tube-for-non-intubated-ercp-anesthesia-a-two-stage-phase-ii-clinical-study-100596938","NCT07051980","Feasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study","Inclusion Criteria:\n\n* Age ≥18 years；\n* The ASA classification ranges from I to III.\n* Patients have signed the informed consent form.\n* Patients scheduled to undergo sedated ERCP examination;\n* The estimated duration of the procedure does not exceed 45 minutes.\n\nExclusion Criteria:\n\n* Severe cardiac dysfunction (\\\u003C4 METs);\n* Severe renal insufficiency (requiring preoperative dialysis);\n* Diagnosed chronic obstructive pulmonary disease (COPD) or other acute\u002Fchronic pulmonary diseases requiring long-term\u002Fintermittent oxygen therapy;\n* Increased intracranial pressure;\n* Upper respiratory tract infections (oral\u002Fnasal\u002Fpharyngeal);\n* Fever (core temperature \\>37.5°C);\n* Confirmed pregnancy or current breastfeeding;\n* Allergy to sedatives (e.g., propofol) or medical adhesives;\n* BMI \\>30 kg\u002Fm²;\n* Current participation in other clinical trials;",{"count":200,"type":22},[25],"Endoscopic retrograde cholangiopancreatography (ERCP) is a technique for evaluating the bile duct, pancreatic duct, and ampulla. Hypoxia is the most common cardiopulmonary complication during ERCP, with a reported rate of 16.2 to 39.2%. The key to preventing hypoxia is to ensure the sufficient oxygenation and ventilation of patients during these procedures. The commonly used approaches to treat hypoxia with a non-instrumented airway are increasing the oxygen flow and lifting the jaw, applying with both hands, displacing the jaw upwards and anteriorly, which allowed the upper airway to remain open. We hypothesized that the supraglottic oxygen delivery via an endotracheal tube can reduce the incidence of hypoxia in patients under deep sedation during ERCP.",[122,123,28,124],[68,690,691,692],"respiratory depression","Hypoxia","Sedation","2025-07-14",{"date":695,"type":40},"2025-07-17",{"date":697,"type":40},"2025-06-12",{"date":106,"type":22},{"name":137,"class":47},{"id":701,"slug":702,"hasResults":12,"nctId":703,"briefTitle":704,"officialTitle":704,"acronym":4,"eligibilityCriteria":705,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":706,"targetDuration":4,"studyType":23,"phases":707,"briefSummary":708,"conditions":709,"keywords":710,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":715,"completionDateStruct":716,"leadSponsor":718,"locationsCount":304},"100593925","phase-2-combo-endoscopy-oropharyngeal-airway-in-sedated-endoscopic-retrograde-cholangiopancreatography-for-patients-100593925","NCT07012772","COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients","Inclusion Criteria:\n\n* Age ≥18 years；\n* The ASA classification ranges from I to III.\n* Patients have signed the informed consent form.\n* Patients scheduled to undergo sedated ERCP examination;\n* The estimated duration of the procedure does not exceed 45 minutes.\n\nExclusion Criteria:\n\n1. Patients with coagulation disorders, tendency for oral\u002Fnasal bleeding, mucosal injury\u002Foccupying lesions, or difficult oropharyngeal airway insertion making airway management unfeasible;\n2. Severe cardiac dysfunction (\\\u003C4 METs);\n3. Severe renal insufficiency (requiring preoperative dialysis);\n4. Child-Pugh class C;\n5. Diagnosed chronic obstructive pulmonary disease (COPD) or other acute\u002Fchronic pulmonary diseases requiring long-term\u002Fintermittent oxygen therapy;\n6. Increased intracranial pressure;\n7. Upper respiratory tract infections (oral\u002Fnasal\u002Fpharyngeal);\n8. Fever (core temperature \\>37.5°C);\n9. Confirmed pregnancy or current breastfeeding;\n10. Allergy to sedatives (e.g., propofol) or medical adhesives;\n11. Emergency procedures;\n12. Multiple trauma injuries;\n13. Peripheral oxygen saturation (SpO2) levels below 95% while breathing room air preoperatively;\n14. BMI \\\u003C18.5 or \\>30 kg\u002Fm²;\n15. Current participation in other clinical trials;\n16. Other conditions deemed ineligible by investigators.",{"count":200,"type":22},[25],"Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of this study is to assess the efficacy of the COMBO Endoscopy Oropharyngeal Airway in reducing the incidence of hypoxia in patients undergoing ERCP under sedation.",[122,123,28,124],[690,711,691,692,68],"The COMBO Endoscopy Oropharyngeal Airway","2025-06-23",{"date":714,"type":40},"2025-06-24",{"date":697,"type":40},{"date":717,"type":22},"2025-12-31",{"name":137,"class":47}]